RT Journal Article SR Electronic T1 Chronic diseases: Perceptions about Covid-19 risk and vaccination JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.17.21253760 DO 10.1101/2021.03.17.21253760 A1 Ricotta, Emily E. A1 Kwan, Jennifer L. A1 Smith, Brianna A. A1 Evans, Nicholas G. YR 2021 UL http://medrxiv.org/content/early/2021/03/24/2021.03.17.21253760.abstract AB Background Individuals with chronic disease may be at higher risk of dying from COVID-19, yet no association has been established between chronic illness and COVID-19 risk perception, engagement with nonpharmaceutical interventions (NPIs), or vaccine acceptance.Methods We surveyed US residents who self-reported a chronic respiratory or autoimmune disease in February 2021. Respondents reported beliefs about the risk of COVID-19 to personal and public health, adoption and support of NPIs, willingness to be vaccinated against COVID-19, and reasons for vaccination willingness. We evaluated the association between disease status and COVID-19 behaviors or attitudes, adjusting for demographic and political factors.Results Compared to healthy controls, chronic disease was associated with increased belief that COVID-19 was a personal (Respiratory = 0.12, 95% confidence interval (CI) = 0.10 - 0.15; Autoimmune = 0.11, CI = 0.08 - 0.14) and public threat (Respiratory = 0.04, CI = 0.02 - 0.06; Autoimmune = 0.03, CI = 0.01 - 0.06), and support for NPIs. Chronic respiratory disease was associated with willingness to be vaccinated (0.6, CI = 0.05 - 0.09). Personal protection was associated with vaccination (Respiratory = 1.08, CI = 1.03 – 1.13; Autoimmune = 1.06, CI = 1.01 – 1.11). Autoimmune disease was associated with fear of a bad vaccine reaction (1.22, CI = 1.06 - 1.41) among those unwilling to be vaccinated.Conclusions In the US, chronic disease status is significantly related to risk perceptions of COVID, support of personal and community risk mitigation measures, and willingness to be vaccinated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNGE was supported by The Greenwall Foundation Faculty Scholars Program, the National Science Foundation (#1734521) and the US Air Force Office of Scientific Research (FA9550-21-1-0142). BAS was supported by the US Naval Academy. JLK and EER were supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The United States Naval Academy IRB approved this research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll deidentified data is archived by the authors and is available on request